Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results
Higher year-end cash and narrower losses accompany an outlook weighed down by a pause in satellite-customer demand.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Precision Optics (POCI) reported fiscal 2026 revenue of $31.5 million, up approximately 65% from fiscal 2025.
Fourth-quarter revenue was $8.8 million, versus $6.2 million a year earlier, as gross margin rose to 25.3% from 13.0%. The quarterly net loss narrowed to $0.1 million from $1.4 million. The full-year net loss narrowed to $3.6 million from $5.8 million, but annual gross margin slipped to 17.2% from 17.8%. Cash was $9.8 million at June 30, 2026, versus $1.8 million a year earlier.
Precision Optics expects fiscal 2027 revenue of $30 million to $33 million and adjusted EBITDA, a non-GAAP earnings measure, of negative $1.2 million to negative $1.7 million. The outlook reflects paused demand from an existing satellite customer; orders are expected to resume in the second half. A public offering issued 3,194,444 shares in fiscal 2026, and the company received a $1.3 million defense follow-on order.
Positive
- Fiscal 2026 revenue rose approximately 65% to $31.5 million from $19.1 million.
- Fourth-quarter revenue rose approximately 42% to $8.8 million from $6.2 million a year earlier.
- Annual production revenue doubled to $28.1 million from $14.2 million.
- Fourth-quarter production revenue rose approximately 57% to $8.0 million from $5.1 million a year earlier.
- Fourth-quarter gross margin rose to 25.3% from 13.0% a year earlier.
- Annual net loss narrowed to $3.6 million, or $0.43 per share, from $5.8 million, or $0.85 per share.
- Fourth-quarter net loss narrowed to $0.1 million from $1.4 million a year earlier.
- Annual adjusted EBITDA loss narrowed to $2.1 million from $3.7 million.
- Fourth-quarter adjusted EBITDA reached $0.4 million, versus negative $0.9 million a year earlier.
- Cash and cash equivalents rose to $9.8 million at June 30, 2026, from $1.8 million a year earlier.
- Public offering added $10,630,678 to stockholders’ equity during fiscal 2026.
- $1.3 million follow-on production order came from a large defense company.
- $3.5 million ophthalmic follow-on order remained in production ramp-up.
- Initial engineering order came from a U.S. space technology company.
- Fiscal 2027 adjusted EBITDA is expected at negative $1.2 million to negative $1.7 million, versus negative $2.1 million in fiscal 2026.
- Satellite-customer orders are expected to resume in the second half of fiscal 2027.
- Peter Thier was appointed senior vice president of sales and marketing.
Negative
- Fiscal 2027 revenue guidance of $30 million to $33 million starts below fiscal 2026 revenue of $31.5 million.
- Satellite-customer demand is paused and weighs on the fiscal 2027 outlook.
- Fiscal 2027 adjusted EBITDA guidance remains negative at $1.2 million to $1.7 million.
- Annual gross margin fell to 17.2% from 17.8% in fiscal 2025.
- 3,194,444 shares issued in the fiscal 2026 public offering diluted existing holders.
- Long-term operating lease liability rose to $2,446,576 at June 30, 2026, from $90,954 a year earlier.
News Explained
The fiscal 2026 public offering generated
Details
Market move: POCI +6.13% vs previous close. FY2026 earnings report
On Sep 28, the day this news came out, the latest delayed price for POCI is 6.13% above the previous close. Our momentum scanner has recorded 18 alerts for this stock so far that day. The latest delayed price is $4.80. Relative volume is exceptionally heavy at 11.3x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Q4 revenue
- $8.8 million
- Q4 2026; quarterly record
- Q4 gross margin
- 25.3%
- Q4 2026, compared with 13.0% in the prior-year quarter
- Q4 net loss
- $(0.1) million
- Q4 2026, compared with $(1.4) million in the prior-year quarter
- Q4 Adjusted EBITDA
- $0.4 million
- Q4 2026, compared with $(0.9) million in the prior-year quarter
- FY revenue
- $31.5 million
- FY2026; fiscal-year record
- FY gross margin
- 17.2%
- FY2026, compared with 17.8% in FY2025
- FY2027 revenue guidance
- $30 million to $33 million
- Year ending June 30, 2027
- FY2027 Adjusted EBITDA guidance
- $(1.2) million to $(1.7) million
- Year ending June 30, 2027
Previous Earnings Reports
-
Record revenue, higher guidance and positive adjusted EBITDA marked the quarter.
-
Record revenue accompanied a gross-margin decline to 2.8% and a net loss.
-
Record revenue coincided with lower gross margin and a quarterly net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adjusted ebitda financial
non-gaap financial
stock-based compensation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Today, September 28, 2026, at 5:00 p.m. ET
LITTLETON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced financial results for its fourth quarter and fiscal year ended June 30, 2026.
Q4 2026 Financial Highlights (3 Months Ended June 30, 2026)
- Revenue was
$8.8 million , a quarterly record, compared to$6.2 million in the same quarter of the previous fiscal year, representing growth of approximately42% , and compared to$8.7 million in the most recent sequential quarter. - Production revenue was
$8.0 million , a quarterly record, compared to$5.1 million in the same quarter of the previous fiscal year, representing growth of approximately57% , and compared to$7.6 million in the most recent sequential quarter. - Gross margin was
25.3% compared to13.0% in the same quarter of the previous fiscal year and compared to23.6% in the most recent sequential quarter. - Net loss for the quarter was
$(0.1) million , compared to a net loss of$(1.4) million in the same quarter of the previous fiscal year and a net loss of$(0.1) million in the most recent sequential quarter. - Adjusted EBITDA was
$0.4 million for the quarter compared to$(0.9) million in the same quarter of the previous fiscal year and$0.3 million in the most recent sequential quarter.
FY 2026 Financial Highlights (Year Ended June 30, 2026)
- Revenue was
$31.5 million , a fiscal year record, compared to$19.1 million in the previous fiscal year, representing growth of approximately65% . - Production revenue doubled to
$28.1 million compared to$14.2 million in the previous fiscal year. - Gross margin was
17.2% compared to17.8% in the previous fiscal year. - Net loss for the fiscal year declined to
$(3.6) million , or$(0.43) per share, from$(5.8) million , or$(0.85) per share, in the previous fiscal year. - Adjusted EBITDA was
$(2.1) million for the fiscal year compared to$(3.7) million in the previous fiscal year, an improvement of approximately$1.6 million . - Cash and cash equivalents were
$9.8 million at June 30, 2026, compared to$1.8 million at June 30, 2025.
Recent Additional Highlights
- Achieved record quarterly revenue from the Company’s existing top-tier aerospace customer and continued strong production of its single-use cystoscopy surgery system.
- Continued ramping production under the previously announced
$3.5 million follow-on order for the single-use ophthalmic program. - Received a
$1.3 million follow-on production order from a large defense company. - Recently announced an initial engineering order from a U.S. space technology company.
- Continued strengthening the Company’s leadership team with the appointment of Peter Thier as Senior Vice President of Sales and Marketing.
FY 2027 Financial Guidance (Year Ending June 30, 2027)
- The Company expects fiscal year 2027 revenue to be in the range of
$30 million to$33 million , similar to fiscal year 2026. The outlook reflects a pause in demand from the Company’s existing satellite customer with growth in single-use medical device programs, renewed defense production, additional programs transitioning into production and new engineering engagements expecting to partly offset this reduction. The Company expects a stronger second half of the year as orders are expected to resume from the existing satellite customer. - The Company expects fiscal year 2027 Adjusted EBITDA to be in a range of
$(1.2) million to$(1.7) million .
“Fiscal 2026 was a year of transformation for Precision Optics, and our fourth-quarter results demonstrate the progress we have made. We delivered record quarterly revenue, and a second consecutive quarter of positive Adjusted EBITDA, closing a year in which revenue grew
“Rebuilding our product development pipeline is a priority led by our new SVP of Sales and Marketing. We received an initial engineering order from a second satellite customer. Although it is still early, we see the potential to build another meaningful, long-term production relationship.”
The following table summarizes the fourth quarter and fiscal year results for the periods ended June 30, 2026 and 2025. Fourth-quarter results are unaudited.
| Three Months Ended June 30 2026 | Three Months Ended June 30 2025 | Year Ended June 30 2026 | Year Ended June 30 2025 | |
| Revenues | $8,774,474 | $6,181,342 | $31,531,765 | $19,091,269 |
| Cost of goods sold | 6,550,806 | 5,382,155 | 26,100,545 | 15,686,836 |
| Gross profit | 2,223,668 | 799,187 | 5,431,220 | 3,404,433 |
| Total operating expenses | 2,330,228 | 2,155,229 | 8,939,828 | 8,955,724 |
| Operating income (loss) | (106,560) | (1,356,042) | (3,508,608) | (5,551,291) |
| Interest income (expense), net | (971) | (44,577) | (116,325) | (227,019) |
| Income (loss) before income taxes | (107,531) | (1,400,619) | (3,624,933) | (5,778,310) |
| Income tax expense (benefit) | (3,744) | 1,936 | 4,958 | 1,936 |
| Net Loss | $(103,787) | $(1,402,555) | $(3,629,891) | $(5,780,246) |
| Earnings (loss) per share, basic | ||||
| Earnings (loss) per share, diluted | ||||
| Weighted average shares, basic | 10,943,843 | 7,690,084 | 8,530,599 | 6,790,466 |
| Weighted average shares, diluted | 10,943,843 | 7,690,084 | 8,530,599 | 6,790,466 |
Conference Call Details
Date and Time: Monday, September 28, 2026, at 5:00 p.m. ET.
Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or (412) 317-5705.
Live Webcast Information: Interested parties can access the conference call via a live webcast, which will be available at https://app.webinar.net/0E4e7l07PjV.
Replay: A teleconference replay of the call will be available for seven days at (855) 669-9658 or (412) 317-0088, replay access code 7128172. A webcast replay will be available at https://app.webinar.net/0E4e7l07PjV.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company focused on leveraging its proprietary micro-optics, multi-channel and ultra-high precision imaging and digital imaging technologies across the medical device, defense/aerospace and satellite communications markets. Through its Systems Manufacturing, Engineering, Ross Optical and Micro-Optics Lab operations, the Company provides services from new product concept and design through volume production. Its in-house optical, mechanical, electrical and systems engineering, prototyping, regulatory support, fabrication, assembly and manufacturing capabilities enable it to develop next-generation solutions for demanding customer requirements. In medical devices, Precision Optics supports minimally invasive and robotic surgery with micro-endoscopes, single-use and reusable endoscopes, digital imaging and related optical assemblies. In defense/aerospace and satellite communications, the Company applies its micro-optics and opto-mechanical expertise to applications requiring high quality and optimized size, weight and power. Ross Optical complements these capabilities through global sourcing, inspection and production of custom and catalog optics. For more information, please visit www.poci.com.
Non-GAAP Financial Measures
Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). In addition to these items, Adjusted EBITDA excludes from Net Income (Loss) the effect of stock-based compensation, interest expense and interest income, depreciation and amortization and income taxes..
This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.
Precision Optics is unable to provide a reconciliation of forward-looking Adjusted EBITDA guidance to net income (loss), the most directly comparable GAAP financial measure, without unreasonable efforts because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including stock-based compensation expense, which may vary significantly based on stock price and other factors outside the Company’s control. The unavailable information could have a significant effect on the Company’s GAAP financial results.
About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws including statements concerning our fiscal year 2027 revenue and Adjusted EBITDA guidance, our expectations regarding customer demand and order resumption, and our anticipated return to record revenue levels. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
| PRECISION OPTICS CORPORATION, INC. Balance Sheets at June 30, 2026 and 2025 | ||||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 9,841,142 | $ | 1,773,735 | ||||
| Accounts receivable, net of allowance for credit losses of | 5,944,412 | 4,336,730 | ||||||
| Inventories, net | 3,829,414 | 3,562,112 | ||||||
| Prepaid expenses | 494,488 | 385,390 | ||||||
| Total current assets | 20,109,456 | 10,057,967 | ||||||
| Fixed Assets: | ||||||||
| Machinery and equipment | 3,410,813 | 3,385,958 | ||||||
| Leasehold improvements | 1,226,171 | 871,356 | ||||||
| Furniture and fixtures | 645,046 | 538,428 | ||||||
| 5,282,030 | 4,795,742 | |||||||
| Less—Accumulated depreciation and amortization | 4,394,317 | 4,261,950 | ||||||
| Net fixed assets | 887,713 | 533,792 | ||||||
| Operating lease right-of-use asset | 2,300,866 | 141,825 | ||||||
| Patents, net | 212,889 | 232,493 | ||||||
| Goodwill | 8,824,210 | 8,824,210 | ||||||
| Total other assets | 11,337,965 | 9,198,528 | ||||||
| TOTAL ASSETS | $ | 32,335,134 | $ | 19,790,287 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Current portion of capital lease obligation | $ | – | $ | 27,368 | ||||
| Current maturities of long-term debt | 577,898 | 577,898 | ||||||
| Accounts payable | 3,582,674 | 2,909,100 | ||||||
| Customer advances | 2,498,501 | 1,821,929 | ||||||
| Accrued compensation and other | 1,843,368 | 764,004 | ||||||
| Operating lease liability | 325,500 | 50,995 | ||||||
| Total current liabilities | 8,827,941 | 6,151,294 | ||||||
| Long-term debt, net of current maturities | 711,305 | 1,289,205 | ||||||
| Operating lease liability, net of current portion | 2,446,576 | 90,954 | ||||||
| Total liabilities | 11,985,822 | 7,531,453 | ||||||
| Stockholders’ Equity: | ||||||||
| Common stock, | 109,728 | 77,147 | ||||||
| Additional paid-in capital | 80,840,105 | 69,152,317 | ||||||
| Accumulated deficit | (60,600,521 | ) | (56,970,630 | ) | ||||
| Total stockholders’ equity | 20,349,312 | 12,258,834 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 32,335,134 | $ | 19,790,287 | ||||
| PRECISION OPTICS CORPORATION, INC. Statements of Operations for the Years Ended June 30, 2026 and 2025 | ||||||||
| 2026 | 2025 | |||||||
| Revenues | $ | 31,531,765 | $ | 19,091,269 | ||||
| Cost of goods sold | 26,100,545 | 15,686,836 | ||||||
| Gross profit | 5,431,220 | 3,404,433 | ||||||
| Research and development expenses, net | 1,033,156 | 1,157,963 | ||||||
| Selling, general and administrative expenses | 7,906,672 | 7,797,761 | ||||||
| Total operating expenses | 8,939,828 | 8,955,724 | ||||||
| Operating loss | (3,508,608 | ) | (5,551,291 | ) | ||||
| Other expense | ||||||||
| Interest expense | (148,129 | ) | (227,019 | ) | ||||
| Interest income | 31,804 | - | ||||||
| Loss before provision for income taxes | (3,624,933 | ) | (5,778,310 | ) | ||||
| Provision for income taxes | 4,958 | 1,936 | ||||||
| Net loss | $ | (3,629,891 | ) | $ | (5,780,246 | ) | ||
| Loss per share: | ||||||||
| Basic and fully diluted | $ | (0.43 | ) | $ | (0.85 | ) | ||
| Weighted average common shares outstanding: | ||||||||
| Basic and fully diluted | 8,530,599 | 6,790,466 | ||||||
| PRECISION OPTICS CORPORATION, INC. Statements of Stockholders’ Equity for the Years Ended June 30, 2026 and 2025 | ||||||||||||||||||||
| Number of Shares | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Equity | ||||||||||||||||
| Balance, June 30, 2024 | 6,073,939 | $ | 60,739 | $ | 61,197,433 | $ | (51,190,384 | ) | $ | 10,067,788 | ||||||||||
| Issuance of common stock in a registered direct offering | 1,538,368 | 15,384 | 6,254,752 | – | 6,270,136 | |||||||||||||||
| Proceeds from exercise of stock option | 71,979 | 721 | 88,329 | – | 89,050 | |||||||||||||||
| Issuance of common stock for consulting services and employees | 30,415 | 303 | 151,395 | – | 151,698 | |||||||||||||||
| Stock-based compensation | – | – | 1,460,408 | – | 1,460,408 | |||||||||||||||
| Net loss | – | – | – | (5,780,246 | ) | (5,780,246 | ) | |||||||||||||
| Balance, June 30, 2025 | 7,714,701 | $ | 77,147 | $ | 69,152,317 | $ | (56,970,630 | ) | $ | 12,258,834 | ||||||||||
| Issuance of common stock in public offering | 3,194,444 | 31,944 | 10,598,734 | – | 10,630,678 | |||||||||||||||
| Proceeds from exercise of stock option | 40,294 | 404 | 39,595 | – | 39,999 | |||||||||||||||
| Issuance of common stock for employee services | 23,353 | 233 | 100,267 | – | 100,500 | |||||||||||||||
| Stock-based compensation | – | – | 949,192 | – | 949,192 | |||||||||||||||
| Net loss | – | – | – | (3,629,891 | ) | (3,629,891 | ) | |||||||||||||
| Balance, June 30, 2026 | 10,972,792 | $ | 109,728 | $ | 80,840,105 | $ | (60,600,521 | ) | $ | 20,349,312 | ||||||||||
| PRECISION OPTICS CORPORATION, INC. Statements of Cash Flows For the Years Ended June 30, 2026 and 2025 | ||||||||
| 2026 | 2025 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | (3,629,891 | ) | $ | (5,780,246 | ) | ||
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities- | ||||||||
| Depreciation and amortization | 279,277 | 212,439 | ||||||
| Stock-based compensation expense | 1,139,692 | 1,612,106 | ||||||
| Non-cash legal expense | – | 34,881 | ||||||
| Non-cash interest expense | 18,433 | 11,563 | ||||||
| Non-cash operating lease expense | 252,336 | 124 | ||||||
| Loss on disposal of fixed assets | 34,506 | – | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | (1,607,682 | ) | (791,239 | ) | ||||
| Inventories | (267,302 | ) | (694,012 | ) | ||||
| Prepaid expenses | (109,098 | ) | (86,026 | ) | ||||
| Accounts payable | 673,574 | 1,511,787 | ||||||
| Contract liabilities | 676,572 | 649,579 | ||||||
| Accrued compensation and other | 989,364 | (76,658 | ) | |||||
| Net cash used in operating activities | (1,550,219 | ) | (3,395,702 | ) | ||||
| Cash Flows from Investing Activities: | ||||||||
| Additional patent costs | (5,564 | ) | (6,264 | ) | ||||
| Proceeds from sale of fixed assets | 3,000 | – | ||||||
| Purchases of property and equipment | (426,786 | ) | (227,209 | ) | ||||
| Net cash used in investing activities | (429,350 | ) | (233,473 | ) | ||||
| Cash Flows from Financing Activities: | ||||||||
| Payment of capital lease obligations | (27,368 | ) | (41,114 | ) | ||||
| Principal payments of long-term debt | (596,333 | ) | (280,440 | ) | ||||
| Payment of debt issuance costs | – | (40,000 | ) | |||||
| Repayments on line of credit | – | (1,000,000 | ) | |||||
| Gross proceeds from registered direct offerings of common stock | – | 6,270,136 | ||||||
| Proceeds from public offering of common stock, net | 10,630,678 | – | ||||||
| Gross proceeds from exercise of stock options | 39,999 | 89,050 | ||||||
| Net cash provided by financing activities | 10,046,976 | 4,997,632 | ||||||
| Net increase in cash and cash equivalents | 8,067,407 | 1,368,457 | ||||||
| Cash and cash equivalents, beginning of year | 1,773,735 | 405,278 | ||||||
| Cash and cash equivalents, end of year | $ | 9,841,142 | $ | 1,773,735 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid during the year for income taxes | $ | 2,600 | $ | 1,936 | ||||
| Cash paid during the year for interest | $ | 129,696 | $ | 216,456 | ||||
| Leasehold improvements financed by landlord | $ | 218,750 | $ | – | ||||
| Issuance of common stock for consulting and employee services | $ | 100,500 | $ | 151,698 | ||||
| Stock based compensation for employee services included in accrued compensation and other | $ | 90,000 | $ | – | ||||
| Operating right-of-use assets obtained in exchange for operating lease liabilities | $ | 2,632,584 | $ | 133,650 | ||||
| PRECISION OPTICS CORPORATION, INC. | ||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | ||||||||||||||||
| ADJUSTED EBITDA | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| June 30 | June 30 | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net Loss (GAAP) | $ | (103,787 | ) | $ | (1,402,555 | ) | $ | (3,629,891 | ) | $ | (5,780,246 | ) | ||||
| Stock based compensation | 397,193 | 439,873 | 1,139,692 | 1,612,106 | ||||||||||||
| Depreciation and amortization | 64,329 | 59,226 | 279,277 | 212,439 | ||||||||||||
| Income Taxes | (3,744 | ) | 1,936 | 4,958 | 1,936 | |||||||||||
| Interest Expense | 32,775 | 44,577 | 148,129 | 227,019 | ||||||||||||
| Interest Income | (31,804 | ) | - | (31,804 | ) | - | ||||||||||
| Adjusted EBITDA (non-GAAP) | $ | 354,962 | $ | (856,943 | ) | $ | (2,089,639 | ) | $ | (3,726,746 | ) | |||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Precision Optics perform in fiscal 2026?
Precision Optics reported $31.5 million in revenue, up approximately 65% from $19.1 million in fiscal 2025. Its net loss narrowed to $3.6 million, or $0.43 per share, from $5.8 million, or $0.85 per share.
What is Precision Optics’ fiscal 2027 outlook?
Precision Optics expects $30 million to $33 million in revenue and adjusted EBITDA of negative $1.2 million to negative $1.7 million for fiscal 2027. Adjusted EBITDA is a non-GAAP earnings measure.
What does Precision Optics expect to offset the satellite-customer demand pause?
Precision Optics expects growth in single-use medical device programs, renewed defense production, additional programs moving into production and new engineering engagements to partly offset the reduction in satellite-customer demand.